ArticleFrontiers in medicine2025
Hepatic tuberculosis induced by rituximab treatment for C1q nephropathy with minimal change disease: a case report.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rituximab is widely used for autoimmune nephropathy. It depletes B cells, potentially increasing infection risk. Tuberculosis is a rare but severe complication of rituximab treatment. We report a case of liver tuberculosis in a patient with C1q nephropathy with Minimal Change Disease (MCD) treated with rituximab. Case presentation: In March 2023, an 81-year-old male patient was admitted to Shaoxing Second Hospital with a 2-month history of bilateral lower extremity edema. He was diagnosed with C1q nephropathy with MCD through renal biopsy. After treatment with 2 g rituximab, his proteinuria was relieved. In October 2024, due to B-cell rebound, 0.5 g of rituximab was added. In December 2023, the patient visited our hospital due to a 7-day fever. Abdominal ultrasound revealed a non-uniform hypoechoic liver mass suspected to be an abscess. Empirical antibiotic treatment was ineffective and the condition worsened. A liver biopsy was immediately performed, and the pathology showed characteristic granulomatous inflammation and patchy coagulative necrosis. The patient was ultimately diagnosed with hepatic tuberculosis and received a 1-year anti-tuberculosis treatment, including rifampicin 450 mg qd, isoniazid 300 mg qd, pyrazinamide 1,500 mg qd, and ethambutol 1,000 mg qd. The patient's temperature returned to normal and abdominal pain was relieved on the third day of treatment. Two months later, a follow-up ultrasound showed a reduction in the left lobe liver mass, and an 8-month CT scan showed complete disappearance of the mass. The patient is currently under follow-up. Conclusion: Rituximab may be an effective treatment option for C1q nephropathy with MCD. Although the risk of infection with rituximab is relatively low, rare infections such as tuberculosis still need to be vigilant, especially in elderly or immunocompromised patients. Additionally, we recommend routine screening for latent tuberculosis in elderly patients with nephropathy and hypogammaglobulinemia before rituximab treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.